Physician profile
Gregory Knutzen
NPI 1871554170
$41,321.67
in general payments reported to CMS, 2019-2025
66 companies · $9,467 in 2025
The $9,467 reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,941 · 2022: $10K · 2023: $7,046 · 2024: $8,460 · 2025: $9,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22K · Education: $1,524 · Consulting Fee: $1,065 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22,283.86 |
| Education | $1,524.43 |
| Consulting Fee | $1,065.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $4,789.40 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,567.06 | 2021-2025 | Opdivo, Reblozyl, Abecma |
| Astrazeneca Pharmaceuticals LP | $2,377.18 | 2021-2025 | Lynparza, Enhertu, Imfinzi |
| Janssen Biotech, INC. | $2,163.02 | 2021-2025 | Erleada, Tecvayli, Darzalex |
| Novartis Pharmaceuticals Corporation | $2,040.62 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $1,919.89 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $1,766.46 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,680.24 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Genzyme Corporation | $1,394.73 | 2021-2025 | |
| Celgene Corporation | $1,389.06 | 2021-2025 | Pomalyst, Reblozyl, Opdualag |
| Astellas Pharma US INC | $1,240.48 | 2021-2025 | Xtandi, Vyloy, Xospata |
| Incyte Corporation | $1,196.96 | 2021-2025 | Jakafi, Jakafi, Monjuvi |
| Genentech USA, INC. | $1,066.14 | 2021-2025 | Venclexta, Polivy, Tecentriq |
| Amgen INC. | $885.95 | 2021-2025 | Lumakras, Imdelltra (Amg757), Kyprolis |
| Eisai INC. | $853.59 | 2021-2025 |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $850.04 | 2021-2025 | Trodelvy |
| Lilly USA, LLC | $844.06 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Aveo Pharmaceuticals, INC. | $802.25 | 2021-2025 | Fotivda |
| Seagen INC. | $769.24 | 2021-2025 | Adcetris, Padcev |
| Regeneron Healthcare Solutions, INC. | $679.61 | 2021-2025 | Libtayo |
| Tg Therapeutics, INC. | $587.18 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $571.76 | 2021-2023 | Imbruvica, Epkinly |
| Daiichi Sankyo INC. | $563.69 | 2021-2025 | Enhertu, Datroway, Vanflyta |
| Abbvie INC. | $537.44 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $525.76 | 2021-2025 | |
| Array Biopharma INC | $511.62 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Karyopharm Therapeutics INC. | $479.96 | 2021-2025 | Xpovio |
| Puma Biotechnology, INC. | $397.13 | 2021-2025 | Nerlynx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $368.24 | 2021-2024 | Gilotrif |
| Takeda Pharmaceuticals U.S.A., INC. | $364.43 | 2022-2024 | Fruzaqla, Iclusig, Ninlaro |
| Sumitomo Pharma America, INC. | $350.75 | 2023-2025 | Orgovyx |
| Dendreon Pharmaceuticals LLC | $317.89 | 2024-2025 | Provenge |
| Emd Serono, INC. | $313.43 | 2021-2025 | |
| Exelixis INC. | $276.84 | 2021-2025 | Cabometyx |
| Myovant Sciences INC. | $273.84 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $271.61 | 2021-2024 | Ultomiris |
| Kite Pharma, INC. | $258.73 | 2021-2023 | |
| Pharmaessentia USA Corporation | $256.08 | 2022-2025 | Besremi |
| Ipsen Biopharmaceuticals, INC | $224.30 | 2021-2024 | Tazverik, Onivyde, Somatuline Depot |
| Adc Therapeutics America, INC. | $208.59 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $197.95 | 2021-2023 | |
| Caris Mpi, INC. | $178.84 | 2025 | Mi Cancer Seek |
| Jazz Pharmaceuticals INC. | $171.64 | 2025 | |
| Taiho Oncology, INC. | $166.99 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $163.21 | 2021-2024 | Xarelto |
| Servier Pharmaceuticals LLC | $141.63 | 2022-2024 | |
| Dova Pharmaceuticals | $131.80 | 2021 | |
| Global Blood Therapeutics, INC. | $129.03 | 2021-2022 | |
| Cti Biopharma Corp. | $107.45 | 2023 | Vonjo |
| Mylan Institutional INC. | $106.05 | 2022-2023 | Fulphila, Ogivri |
| Mirati Therapeutics, INC. | $103.41 | 2023-2024 | Krazati |
| Secura Bio, INC. | $95.22 | 2025 | Copiktra |
| Rigel Pharmaceuticals, INC. | $93.56 | 2022-2024 | Tavalisse, Rezlidhia |
| Tempus Ai, INC | $93.09 | 2024 | |
| Agios Pharmaceuticals, INC. | $91.83 | 2025 | Pyrukynd |
| Legend Biotech USA INC. | $84.79 | 2024-2025 | Carvykti |
| Iovance Biotherapeutics, INC. | $57.48 | 2025 | Amtagvi |
| Menarini Silicon Biosystems, INC. | $49.91 | 2024 | |
| Springworks Therapeutics, INC. | $47.82 | 2025 | Ogsiveo |
| Emmaus Medical, INC. | $46.32 | 2021-2022 | |
| Immunocore Limited | $28.69 | 2024 | Kimmtrak |
| Blueprint Medicines Corporation | $27.13 | 2023 | Ayvakit |
| Adaptive Biotechnologies Corporation | $24.93 | 2024 | Clonoseq |
| Terumo Bct, INC. | $17.91 | 2022 | |
| Novo Nordisk INC | $15.88 | 2021 | |
| Stemline Therapeutics INC. | $13.86 | 2023 | Elzonris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Knutzen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.